Q3 snapshot: The IPO market shows fresh signs of improvement, but the biotech crunch continues to bite

The biotech IPO market crashed hard last year, but we’re seeing the window creak open in a steady upward trend in 2023 that bodes for better times — though it’s a long, long way from a boom.

Chris Dokomajilar at DealForma is back crunching the numbers, and we’ll start with signs that biotechs are brushing the dust off their S-1s and going back to the market in search of cash to grow their businesses.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

FDA approves Daiichi Sankyo’s new first-line AML drug quizartinib with boxed warning for heart disorders

Patients with a rarer form of acute myeloid leukemia now have a frontline treatment option for the first time, thanks to the FDA’s approval of

July 22, 2023

Medical marijuana companies are using pharma’s sales tactics with little of the same scrutiny

WASHINGTON — Medical marijuana companies sell medicine, just like pharmaceutical companies. But they’re not playing by the same rules — and that’s putting patients at

December 21, 2023

The Latest on Targeted Agents, Immunotherapy for Endometrial Cancer

Molecularly targeted therapy is proving promising for endometrial cancer. Not only are molecular tests able to group or split endometrial cancers into specific molecular groups,

July 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.